Blog
Featured post
Truveta Data now includes more than 120 million de-identified patients
Truveta has also partnered with more than 100 organizations across life sciences, healthcare, public health, academic research organizations, and others to use regulatory-grade EHR data enabling scientifically rigorous research.
Exploring mental health-related emergency department visits
In an exclusive analysis for the Wall Street Journal, Truveta Research explored mental health-related emergency department visits. The rate of ED encounters related to mental...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through November 2024
Between the last week of October and the last week of November, there was a 58.8% increase in respiratory virus-associated hospitalizations. For infants and children under the...
Exploring first-time GLP-1 prescriptions and new comorbidity diagnoses
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea...
Adderall shortage: Exploring first-time Adderall prescriptions and fill rates
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of...
Adderall shortage: Exploring first-time ADHD diagnosis rates
The rate of first-time ADHD diagnoses has increased since 2021. The largest increases in first-time ADHD diagnosis rates were seen in the 30-44-year-old and 45-64-year-old age...
Combating respiratory viruses with EHR data: Key use cases for life sciences and public health
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity...
An AI platform that supports adjacencies
In the final article in this series, I will share some thoughts on meeting the following challenge: How to rapidly support new AI scenarios and adjacencies through reuse and...
A year later: New GLP-1 clinical trial results validate Truveta’s real-world data study
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through October 2024
RSV-associated hospitalizations increased 191.5% throughout October 2024. RSV-associated hospitalizations also increased in vulnerable populations with a 233.3% in infants and...